Recent News
As chairman and CEO of Kleo Pharmaceuticals, a private immuno-oncology company developing next-generation bispecific compounds designed to enhance the […] Read More...
Watch the Video to Learn More
Partnering Opportunities
Our technologies enable us to rapidly develop novel immunotherapies against targets of interest with potential partners.
Our Lead Programs
Kleo is rapidly advancing multiple candidates against a range of hematological and solid tumors
Partnering Opportunities
Our technologies enable us to rapidly develop novel immunotherapies against targets of interest with potential partners.
Our Lead Programs
Kleo is rapidly advancing multiple candidates against a range of hematological and solid tumors
Our Technologies
News
Luther Turmelle April 1, 2020 Updated: April 1, 2020 4:54 p.m. Doug Manion, CEO of Kleo Pharmaceuticals in New Haven, right, meets with […] Read More
Kleo’s First Non-Oncology Application of Its Antibody Recruiting Molecule (ARM™) to Be Tested in Combination with GCLC’s NK Cells as […] Read More
Former Board Chairman Dr. Tom Lynch, New President and Director at Fred Hutchinson Cancer Research Center, to Remain a Consultant […] Read More
KP1237, a CD38-Targeting Antibody Recruiting Molecule (ARM™), to Be Tested in Combination with NK Cells to Treat Post-Transplant Multiple Myeloma […] Read More
Events
AACR – American Association for Cancer Research
ASCO – American Society of Clinical Oncology
BIO International Convention
